Your browser is no longer supported. Please, upgrade your browser.
Settings
CHRS Coherus Biosciences, Inc. daily Stock Chart
CHRS [NASD]
Coherus Biosciences, Inc.
Index- P/E- EPS (ttm)-3.34 Insider Own0.20% Shs Outstand51.16M Perf Week-9.19%
Market Cap1.04B Forward P/E- EPS next Y-2.23 Insider Trans0.00% Shs Float43.92M Perf Month1.76%
Income-136.70M PEG- EPS next Q-1.23 Inst Own87.10% Short Float10.23% Perf Quarter-11.57%
Sales177.90M P/S5.82 EPS this Y49.50% Inst Trans20.77% Short Ratio7.99 Perf Half Y-27.94%
Book/sh1.60 P/B12.66 EPS next Y- ROA-64.40% Target Price7.35 Perf Year12.44%
Cash/sh3.42 P/C5.93 EPS next 5Y2.00% ROE-773.80% 52W Range14.00 - 31.98 Perf YTD-28.06%
Dividend- P/FCF- EPS past 5Y-44.33% ROI-96.00% 52W High-36.68% Beta-
Dividend %- Quick Ratio4.40 Sales past 5Y- Gross Margin- 52W Low44.64% ATR1.24
Employees169 Current Ratio4.40 Sales Q/Q-98.40% Oper. Margin-69.70% RSI (14)45.76 Volatility5.76% 6.14%
OptionableYes Debt/Eq1.29 EPS Q/Q8.20% Profit Margin-76.90% Rel Volume1.04 Prev Close20.20
ShortableYes LT Debt/Eq1.29 EarningsMay 08 AMC Payout- Avg Volume562.24K Price20.25
Recom3.00 SMA20-4.02% SMA50-2.05% SMA200-21.56% Volume582,788 Change0.25%
May-05-17Initiated BMO Capital Markets Outperform $54
Oct-19-16Initiated Robert W. Baird Outperform $40
Sep-07-16Initiated Maxim Group Buy $43
Jul-27-16Initiated Citigroup Buy $36
Jan-20-16Initiated Credit Suisse Outperform
May-18-17 11:17AM  [$$] AbbVie: It's the Pipeline, Not the Coherus Ruling Barrons.com
09:23AM  AbbVie Down on Humira Patent Loss: Is More Damage in Store? Zacks
May-17-17 05:02PM  AbbVie Loses Key Humira Patent In Battle With Small-Cap Biotech Investor's Business Daily +7.94%
12:11PM  Biotech And Pharma Industry And Stock News Investor's Business Daily
12:10PM  Why This Humira Patent Loss Might Not Be What You Think 24/7 Wall St.
10:53AM  AbbVie Stock Lower on Humira Patent Ruling TheStreet.com
May-16-17 07:29PM  Coherus BioSciences Prevails in 135 IPR Decision GlobeNewswire
May-13-17 09:15PM  Edited Transcript of CHRS earnings conference call or presentation 8-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-12-17 04:59PM  Coherus BioSciences, Inc. Value Analysis (NASDAQ:CHRS) : May 12, 2017 Capital Cube
08:42AM  Are Options Traders Betting on a Big Move in COHERUS BIOSCIENCES (CHRS) Stock? Zacks
May-11-17 08:26AM  Coherus BioSciences, Inc. breached its 50 day moving average in a Bullish Manner : CHRS-US : May 11, 2017 Capital Cube
May-09-17 08:45PM  Edited Transcript of CHRS earnings conference call or presentation 8-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-08-17 05:21PM  Coherus BioSciences reports 1Q loss Associated Press
04:01PM  Coherus BioSciences Reports First Quarter 2017 Corporate Highlights and Financial Results GlobeNewswire
10:00AM  Investor Network: Coherus BioSciences, Inc. to Host Earnings Call Accesswire
May-05-17 11:17AM  The Prospects For CHS-3351, Coherus' Most Underappreciated Asset Benzinga
May-01-17 09:00AM  Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in May GlobeNewswire +5.73%
Apr-25-17 03:28PM  ETFs with exposure to Coherus BioSciences, Inc. : April 25, 2017 Capital Cube +5.77%
08:30AM  Coherus BioSciences Completes Patent Dance Exchange with Amgen for Neulasta Biosimilar GlobeNewswire
Apr-24-17 09:00AM  Coherus BioSciences to Report First Quarter 2017 Financial Results on May 8th GlobeNewswire
Apr-05-17 04:30PM  ETFs with exposure to Coherus BioSciences, Inc. : April 5, 2017 Capital Cube
Mar-27-17 04:00PM  Coherus BioSciences Appoints Erik Wiberg as Executive Vice President of Corporate Development GlobeNewswire
Mar-20-17 11:50AM  Coherus BioSciences, Inc. :CHRS-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Capital Cube
Mar-17-17 01:04PM  COHERUS BIOSCIENCES, INC. Financials
Mar-16-17 09:51AM  Coherus BioSciences, Inc. :CHRS-US: Earnings Analysis: 2016 By the Numbers : March 16, 2017 Capital Cube
Mar-14-17 06:07AM  COHERUS BIOSCIENCES, INC. Files SEC form 10-K, Annual Report -5.44%
Mar-13-17 11:02PM  Edited Transcript of CHRS earnings conference call or presentation 13-Mar-17 8:30pm GMT Thomson Reuters StreetEvents
04:30PM  Coherus BioSciences Inc Earnings Call scheduled for 4:30 pm ET today
04:12PM  Coherus BioSciences reports 4Q loss Associated Press
04:10PM  COHERUS BIOSCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:01PM  Coherus BioSciences Reports Fourth Quarter and Full Year 2016 Corporate Highlights and Financial Results GlobeNewswire
07:07AM  Q4 2016 Coherus BioSciences Inc Earnings Release - After Market Close
Mar-06-17 04:03PM  COHERUS BIOSCIENCES, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:00AM  Coherus Addresses Trade Secret Action Filed by Amgen GlobeNewswire
Mar-03-17 04:26PM  COHERUS BIOSCIENCES, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Mar-02-17 04:00PM  Statement by Coherus CEO Regarding Biosimilars User Fees GlobeNewswire
09:22AM  5 Small-Cap Biotech Stocks to Buy in March Motley Fool
08:30AM  Coherus Announces CHS-1420 Pharmacokinetic Clinical Bioequivalence Study Meets Primary Endpoint GlobeNewswire
Mar-01-17 09:00AM  Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in March GlobeNewswire +5.51%
Feb-21-17 04:01PM  Coherus BioSciences to Report Fourth Quarter and Full Year 2016 Financial Results on March 13th GlobeNewswire
Feb-17-17 08:30AM  Coherus BioSciences Announces New Employment Inducement Grants GlobeNewswire
Feb-13-17 05:13PM  COHERUS BIOSCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Sta
Feb-08-17 12:03PM  Why Coherus Biosciences Is Falling Today at Motley Fool -11.44%
11:39AM  Coherus Biosciences Inc (CHRS) Could Be A Discount Entry On The Pullback at Insider Monkey
08:30AM  Coherus Prices Public Offering of Common Stock GlobeNewswire
Feb-07-17 04:04PM  Coherus Announces Proposed Public Offering of Common Stock GlobeNewswire
Jan-31-17 04:03PM  COHERUS BIOSCIENCES, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
03:40PM  Coherus BioSciences Files Four Petitions for Inter Partes Review Against AbbVies HUMIRA® Formulation Patent 9,085,619 GlobeNewswire
Jan-27-17 01:34PM  Coherus BioSciences, Inc. Value Analysis (NASDAQ:CHRS) : January 27, 2017
Jan-26-17 07:49AM  Coherus BioSciences, Inc. breached its 50 day moving average in a Bullish Manner : CHRS-US : January 26, 2017
Jan-19-17 12:38PM  ETFs with exposure to Coherus BioSciences, Inc. : January 19, 2017
Jan-13-17 09:55AM  Coherus Offers Positive Phase III Data on Humira Biosimilar
Jan-10-17 08:45AM  Coherus BioSciences Announces Positive Topline 24-Week Treatment Phase Three Results for CHS-1420 (HUMIRA® Biosimilar Candidate) in Patients with Psoriasis GlobeNewswire
08:38AM  Coherus BioSciences, Inc. breached its 50 day moving average in a Bearish Manner : CHRS-US : January 10, 2017
Jan-04-17 09:00AM  Coherus BioSciences Management to Present at The 35th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-19-16 07:19AM  Coherus BioSciences, Inc. breached its 50 day moving average in a Bullish Manner : CHRS-US : December 19, 2016
Dec-07-16 12:30PM  Coherus BioSciences to Present at BMO Prescriptions for Success Healthcare Conference on December 14th GlobeNewswire
11:01AM  Coherus BioSciences, Inc. Value Analysis (NASDAQ:CHRS) : December 7, 2016
Dec-06-16 07:16AM  Coherus BioSciences, Inc. breached its 50 day moving average in a Bullish Manner : CHRS-US : December 6, 2016
Nov-30-16 04:04PM  COHERUS BIOSCIENCES, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Nov-29-16 09:00AM  Coherus Marketing Authorization Application to European Medicines Agency for CHS-1701 (Pegfilgrastim Biosimilar Candidate) Accepted GlobeNewswire
Nov-28-16 05:27AM  Is The Rubicon Project Inc (RUBI) A Good Stock To Buy? at Insider Monkey
Nov-17-16 07:50PM  Coherus BioSciences Announces New Employment Inducement Grants GlobeNewswire
Nov-10-16 05:00AM  Coherus BioSciences posts 3Q profit
Nov-09-16 09:31PM  Edited Transcript of CHRS earnings conference call or presentation 9-Nov-16 9:30pm GMT +12.22%
04:30PM  Coherus BioSciences Inc Earnings Call scheduled for 4:30 pm ET today
04:14PM  COHERUS BIOSCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:01PM  Coherus BioSciences Reports Third Quarter 2016 Operating and Financial Results GlobeNewswire
10:14AM  AbbVie Inc (ABBV) Wins Patent Battle Against Coherus Biosciences Inc (CHRS) at Insider Monkey
07:07AM  Q3 2016 Coherus BioSciences Inc Earnings Release - After Market Close
Nov-08-16 04:05PM  Coherus Biosciences' Humira Petition Denied -5.66%
10:15AM  AbbVie Crushes Humira Patent Challenge (ABBV, CHRS) at Investopedia
08:12AM  Drug Stock Earnings to Watch on Nov 9: MYL, IONS & More
Nov-07-16 07:16PM  AbbVie Inc (ABBV) Stock: Skyrocketing On IP Chatter | Coherus Biosciences Inc (CHRS) Stock Tanking at Insider Monkey -9.06%
04:36PM  COHERUS BIOSCIENCES, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
03:35PM  AbbVie: Take That Coherus! at Barrons.com
03:03PM  Why Coherus Biosciences 15% Dip Provides An Opportunity To Buy
02:51PM  Why Coherus BioSciences, Inc. Is Dropping Today at Motley Fool
02:30PM  Coherus BioSciences Inc Conference Call on Patent Trial and Appeal Board decision scheduled for 2:30 pm ET today
02:05PM  AbbVie Stock Higher on Humira Patent Win
12:40PM  Coherus BioSciences Receives Decision Denying Institution of the 166 IPR Related to AbbVies HUMIRA® Formulation GlobeNewswire
Nov-04-16 04:30PM  Coherus BioSciences Announces New Employment Inducement Grants GlobeNewswire
Nov-01-16 04:30PM  Coherus BioSciences to Report Third Quarter 2016 Financial Results on November 9th GlobeNewswire
09:00AM  Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in November GlobeNewswire
Oct-31-16 08:34AM  Coherus BioSciences, Inc. breached its 50 day moving average in a Bearish Manner : CHRS-US : October 31, 2016
Oct-28-16 05:07PM  COHERUS BIOSCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Ex
Oct-21-16 09:00AM  Coherus BioSciences Announces New Employment Inducement Grants GlobeNewswire
Oct-20-16 08:20AM  Coherus BioSciences, Inc. breached its 50 day moving average in a Bullish Manner : CHRS-US : October 20, 2016
Oct-19-16 05:40AM  Coverage initiated on Coherus BioSciences by Robert W. Baird
Oct-13-16 04:28PM  3 Top Game-Changing Stocks to Buy Today at Motley Fool
Oct-07-16 04:11PM  COHERUS BIOSCIENCES, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits +7.09%
Oct-06-16 05:53PM  Coherus BioSciences Announces FDA Acceptance of 351(k) Biologics License Application to U.S. Food and Drug Administration for CHS-1701 (Pegfilgrastim Biosimilar Candidate) GlobeNewswire
04:54PM  COHERUS BIOSCIENCES, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
04:09PM  Coherus BioSciences Completes two Pharmacokinetic Bioequivalence Studies of CHS-0214 GlobeNewswire
Oct-05-16 09:14AM  Momenta, Coherus BioSciences Are Both Good Options in the Biosimilar Space
Oct-03-16 12:57PM  Coherus Biosciences Could Be First-To-Market With A Neulasta Biosimilar
Sep-30-16 10:27AM  Coherus BioSciences, Inc. Value Analysis (NASDAQ:CHRS) : September 30, 2016
Sep-29-16 08:31AM  Coherus BioSciences, Inc. breached its 50 day moving average in a Bearish Manner : CHRS-US : September 29, 2016 -8.68%
Sep-28-16 02:53PM  [$$] Coherus, Momenta Set for Different Outcomes at Barrons.com -6.89%
Sep-27-16 04:08PM  COHERUS BIOSCIENCES, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Financial Statements an
Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The company's product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, nonsmall cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. Its product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, Behcet's Disease, Crohn's Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular (wet) age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Coherus Biosciences, Inc. has license agreement with Daiichi Sankyo Company, Limited; Baxalta Incorporated, Baxalta US Inc., and Baxalta GmbH; Genentech, Inc.; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.